TTBA Talk 13
Tue., Feb 21, 2017 8-9 pm (CST)
Austin | UT Austin, BME5.202I Houston | BCM N1318 Dallas | UT Southwestern, NA 5.218 Texas A&M | ILSB3147
Biotech Development in Taiwan and Personal Experiences
Henry C. Liu, 劉朝瀚, Ph.D.
Vice Director, Lihpao Biomedical Lab at Taipei Veterans General Hospital
Dr. Liu works at Lihpao Life Corp., serving as Vice Director of Lihpao Biomedical Lab at Taipei Veterans General Hospital. As a project manager of clinical sequencing service and new drug development, he carries out several projects related to using genomic sequencing platform to identify biomarkers associated with disease prognosis, treatment outcome, and drug resistance. In the new drug development, he helps developing a platform for drug delivery, which is used to target against cancer and enzyme-deficient diseases with a cost-effective and oral delivery.
Henry Liu completed his Ph.D. in Bioengineering at UCSD under the guidance of Dr. Sanjay Nigam and Dr. Shu Chien, in which his main focus of study is the interaction between kidney functions and cellular metabolisms using methods of computational chemistry and data-mining. Prior to his Ph.D., Henry received B.S. degree in Bioengineering at UC Berkeley.
劉朝瀚博士任職於麗寶生醫，擔任北榮麗寶醫學實驗室副主任。劉博士參與多項精準醫學臨床如何應用的研究計畫 - 其包含兩大方向，基因定序以及新藥開發。在基因定序的研究計畫中，劉博士參與如何將基因研究應用於癌症早期預測、治療、以及術後追蹤和其他遺傳性疾病的早期診斷。同時，劉博士也參與新藥開發的平台開發，此藥物平台可用於癌症治療以及其他遺傳性疾病治療。從精準診斷到精準治療，期望提供給病人新一代的全方位治療方式.
劉博士於加州大學聖地牙哥分校取得生物工程博士學位，師承於Dr. Sanjay Nigam & Dr. Shu Chien，主要研究方向為腎臟功能與新陳代謝的關聯性，找尋其重要關聯性並在體外探索如何複製腎臟功能。在攻讀博士學位之前,劉博士大學畢業於加州大學柏克萊分校，在此期間，參與心血管再生的研究。